Boston Scientific trades around $61, with analyst price targets ranging from $69 (conservative) to $124 (optimistic), implying substantial upside. Abbott Laboratories trades near $95 against an optimistic target of $143. Both trade at or near 52-week lows while Wall Street analysts maintain bullish ratings.
Both benefit from an aging global population requiring more cardiac procedures, glucose monitoring, and cancer diagnostics. Healthcare spending has grown to $5.9 trillion annually as of February 2026, up from $5.6 trillion in January 2025. This structural tailwind makes the price declines difficult to justify on fundamentals alone.
This post originally appeared at 24/7 Wall St.